Judge toss­es PhRMA's suit over drug price ne­go­ti­a­tions in a win for the Biden ad­min­is­tra­tion

Last year
Pharma
Law

Roche walks away from Re­pare sol­id tu­mor deal just weeks af­ter $40M mile­stone pay­out

Last year
Deals
R&D

KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

Last year
R&D

Stake­hold­ers brace for bumps in rare pe­di­atric dis­ease PRV reau­tho­riza­tion

Last year
Pharma
FDA+

House Re­pub­li­cans take is­sue with DO­J's han­dling of Mod­er­na's Covid vac­cine patents

Last year
Coronavirus

Neu­rol­o­gists val­ue speed and ef­fi­ca­cy over safe­ty for ALS pipeline drugs, study finds

Last year
Pharma
Marketing

Gilead­'s newest ac­qui­si­tion: a liv­er dis­ease drug with $1B in peak sales po­ten­tial

Last year
Deals

FTC re­view pe­ri­ods end for Ab­b­Vie-Im­muno­Gen $10.1B deal and $4B BMS-Rayze­Bio buy­out

Last year
Deals
Pharma

Co­me­di­ans dri­ve Vi­iV’s new rideshar­ing se­ries about HIV pre­ven­tion

Last year
Marketing

Take­da wins long-await­ed US ap­proval for first oral drug for eosinophilic esophagi­tis

Last year
Pharma
FDA+

FDA ad­dress­es ex­pand­ed use of da­ta mon­i­tor­ing com­mit­tees in draft guid­ance

Last year
Pharma
FDA+

Lari­mar Ther­a­peu­tics shares key bio­mark­er da­ta, aims for ac­cel­er­at­ed ap­proval for Friedre­ich’s atax­ia drug

Last year
R&D

Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date 

Last year
News Briefing

In­fec­tious dis­ease biotech halts late-stage tri­al due to sub­par ef­fi­ca­cy, shares plum­met 70%

Last year
R&D

A sweep­ing form of search-and-re­place edit­ing has come for mR­NA

Last year
R&D
In Focus

Gilead to snap up liv­er dis­ease biotech CymaBay for $4.3B

Last year
Deals
Pharma

CSL shares down 5% af­ter post-heart at­tack drug dis­ap­points in late-stage test

Last year
R&D

Cor­rec­tion: Iambic says new AI mod­el bests Al­phaFold as pro­tein mod­els rock­et ahead

Last year
R&D
AI

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Last year
Financing
Startups

Pfiz­er joins Su­per Bowl ad line­up, toast­ing Katal­in Karikó and oth­er in­no­va­tors with 'Here’s to Sci­ence' spot

Last year
Pharma
Marketing

No­vo Hold­ings’ $16.5B bid for Catal­ent; No­var­tis’ $2.9B bolt-on; End­points Slack in­ter­view with John Evans; and ...

Last year
Weekly

No­vo Nordisk se­cures first two wins in le­gal bat­tle against com­pound­ing phar­ma­cies, well­ness cen­ters

Last year
Pharma
Law

As­traZeneca en­cour­ages NHL fans to get 'body checked' for can­cer

Last year
Pharma
Marketing

FDA fi­nal­izes rule on us­ing mas­ter files in bi­o­log­ics ap­pli­ca­tions

Last year
Pharma
FDA+
First page Previous page 202203204205206207208 Next page Last page
A service from the Financial Times